Reports Q2 revenue $69,000 vs $198,000 last year. “The strength of our recent clinical and preclinical findings for VYN202 provides a compelling scientific foundation as we determine the best path forward for the VYN202 program,” said David Domazalski, President and Chief Executive Officer of VYNE. “In conjunction, we have implemented cost reductions that are expected to extend our cash runway into the first half of 2027, giving us additional flexibility during this period.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- VYNE Earnings this Week: How Will it Perform?
- Watch Out! Analysts Have Recently Downgraded These Stocks
- Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
- VYNE Therapeutics downgraded to Neutral from Buy at BTIG
- VYNE Therapeutics: Buy Rating Supported by Promising VYN202 Prospects Amidst Challenges